The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Open accessAbstract
BACKGROUND: Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term hemodialysis. Paricalcitol, a new vitamin D analogue, appears to lessen the elevations in serum calcium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D. METHODS: We conducted a historical cohort study to compare the 36-month survival rate among patients undergoing long-term hemodialysis who started to receive treatment with paricalcitol (29,021 patients) or calcitriol (38,378 patients) between 1999 and 2001. Crude and adjusted survival rates were calculated and stratified analyses were performed. A subgroup of 16,483 patients who switched regimens was also evaluated. RESULTS: The mortality rate among patients receiving paricalcitol was 3417 per 19,031 person-years (0.180 per person-year), as compared with 6805 per 30,471 person-years (0.223 per person-year) among those receiving calcitriol (P<0.001). The difference in survival was significant at 12 months and increased with time (P<0.001). In the adjusted analysis, the mortality rate was 16 percent lower (95 percent confidence interval, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-treated patients. A significant survival benefit was evident in 28 of 42 strata examined, and in no stratum was calcitriol favored. At 12 months, calcium and phosphorus levels had increased by 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percent, respectively, in the calcitriol group (P<0.001). The two-year survival rate among patients who switched from calcitriol to paricalcitol was 73 percent, as compared with 64 percent among those who switched from paricalcitol to calcitriol (P=0.04). CONCLUSIONS: Patients who receive paricalcitol while undergoing long-term hemodialysis appear to have a significant survival advantage over those who receive calcitriol. A prospective, randomized study is critical to confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Goodman, W. G., Goldin, J., Kuizon, B. D., Yoon, C., Gales, B., Sider, D., Wang, Y., Chung, J., Emerick, A., Greaser, L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422003 · Cited by 2,509
Block, G., Hulbert-Shearon, T., Levin, N., & Port, F. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9531176 · Cited by 2,354
Oodman, W. I. G. G., Oldin, J. O. G., Uizon, D. K., Oon, C. H. Y., Ales, B. A. G., Ider, D. O. S., Ang, W. C., Oanie, J., Hung, C., Merick, A. L. E., et al. (2000) · Cited by 2,191
Lowrie, E. G., & Lew, N. L. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70364-5 · Cited by 1,976
Self-citationSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Chertow, G. M., Burke, S. K., Raggi, P., & for the Treat to Goal Working Group (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00434.x · Cited by 1,462
Owen, W. F., Lew, N. L., Liu, Y., Lowrie, E. G., & Lazarus, J. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291404 · Cited by 1,404
Self-citationGANESH, S. K., STACK, A. G., LEVIN, N. W., HULBERT-SHEARON, T., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102131 · Cited by 1,204
Oh, J., Wunsch, R., Turzer, M., Bahner, M., Raggi, P., Querfeld, U., Mehls, O., & Schaefer, F. (2002) · Circulation · doi:10.1161/01.cir.0000020222.63035.c0 · Cited by 722
Cited by
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
Self-citationVitamin D signalling pathways in cancer: potential for anticancer therapeutics
Deeb, K. K., Trump, D. L., & Johnson, C. S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2196 · Cited by 1,419
Dobnig, H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.12.1340 · Cited by 1,209
Isakova, T. (2011) · JAMA · doi:10.1001/jama.2011.826 · Cited by 1,020
Vascular Calcification: Pathobiological Mechanisms and Clinical Implications
Johnson, R. C., Leopold, J. A., & Loscalzo, J. (2006) · Circulation Research · doi:10.1161/01.res.0000249379.55535.21 · Cited by 944
Fraser, W. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60507-9 · Cited by 934
Vitamin D levels and early mortality among incident hemodialysis patients
Wolf, M., Shah, A., Gutierrez, O., Ankers, E., Monroy, M., Tamez, H., Steele, D., Chang, Y., Camargo, C. A., Tonelli, M., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002451 · Cited by 789
Self-citationActivated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernán, M. A., Camargo, C. A., & Thadhani, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070573 · Cited by 782
Self-citationYoung, E. W., Albert, J. M., Satayathum, S., Goodkin, D. A., Pisoni, R. L., Akiba, T., Akizawa, T., Kurokawa, K., Bommer, J., Piera, L., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00185.x · Cited by 753
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
de Zeeuw, D., Agarwal, R., Amdahl, M., Audhya, P., Coyne, D., Garimella, T., Parving, H.-H., Pritchett, Y., Remuzzi, G., Ritz, E., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61032-x · Cited by 695
Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options
Cunningham, J., Locatelli, F., & Rodriguez, M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06040710 · Cited by 646
The Vitamin D Epidemic and its Health Consequences
Holick, M. F. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.11.2739s · Cited by 579
Xiang, W., Kong, J., Chen, S., Cao, L.-P., Qiao, G., Zheng, W., Liu, W., Li, X., Gardner, D. G., & Li, Y. C. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00224.2004 · Cited by 570
Thadhani, R., Appelbaum, E., Pritchett, Y., Chang, Y., Wenger, J., Tamez, H., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., et al. (2012) · JAMA · doi:10.1001/jama.2012.120 · Cited by 567
Self-citationVascular Calcification: The Killer of Patients with Chronic Kidney Disease
Mizobuchi, M., Towler, D., & Slatopolsky, E. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070692 · Cited by 542
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients
Suki, W. N., Zabaneh, R., Cangiano, J. L., Reed, J., Fischer, D., Garrett, L., Ling, B. N., Chasan-Taber, S., Dillon, M. A., Blair, A. T., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002466 · Cited by 526
Vitamin D levels and patient outcome in chronic kidney disease
Ravani, P., Malberti, F., Tripepi, G., Pecchini, P., Cutrupi, S., Pizzini, P., Mallamaci, F., & Zoccali, C. (2009) · Kidney International · doi:10.1038/ki.2008.501 · Cited by 437
Osteogenic regulation of vascular calcification: an early perspective
Vattikuti, R., & Towler, D. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00552.2003 · Cited by 397
Zhou, C., Lu, F., Cao, K., Xu, D., Goltzman, D., & Miao, D. (2008) · Kidney International · doi:10.1038/ki.2008.101 · Cited by 391
Update on fibroblast growth factor 23 in chronic kidney disease
Wolf, M. (2012) · Kidney International · doi:10.1038/ki.2012.176 · Cited by 391
Self-citationMortality risk among hemodialysis patients receiving different vitamin D analogs
Tentori, F., for the Medical Directors of Dialysis Clinic Inc., Hunt, W. C., Stidley, C. A., Rohrscheib, M. R., Bedrick, E. J., Meyer, K. B., Johnson, H. K., & Zager, P. G. (2006) · Kidney International · doi:10.1038/sj.ki.5001868 · Cited by 391
Antiproteinuric effect of oral paricalcitol in chronic kidney disease
Agarwal, R., Acharya, M., Tian, J., Hippensteel, R. L., Melnick, J. Z., Qiu, P., Williams, L., & Batlle, D. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00755.x · Cited by 377
Phosphorus Binders and Survival on Hemodialysis
Isakova, T., Gutie[Combining Acute Accent]rrez, O. M., Chang, Y., Shah, A., Tamez, H., Smith, K., Thadhani, R., & Wolf, M. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008060609 · Cited by 375
Self-citationVitamin D in Chronic Kidney Disease and Dialysis Patients
Jean, G., Souberbielle, J., & Chazot, C. (2017) · Nutrients · doi:10.3390/nu9040328 · Cited by 355
Jean, G., Terrat, J.-C., Vanel, T., Hurot, J.-M., Lorriaux, C., Mayor, B., & Chazot, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp191 · Cited by 351
Shoji, T., Shinohara, K., Kimoto, E., Emoto, M., Tahara, H., Koyama, H., Inaba, M., Fukumoto, S., Ishimura, E., Miki, T., et al. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg513 · Cited by 351
Arterial calcification and bone physiology: role of the bone–vascular axis
Thompson, B., & Towler, D. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.36 · Cited by 337
Bodyak, N., Ayus, J. C., Achinger, S., Shivalingappa, V., Ke, Q., Chen, Y.-S., Rigor, D. L., Stillman, I., Tamez, H., Kroeger, P. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611202104 · Cited by 333
Self-citationAlborzi, P., Patel, N. A., Peterson, C., Bills, J. E., Bekele, D. M., Bunaye, Z., Light, R. P., & Agarwal, R. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.113159 · Cited by 331
Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl
Moe, S. M., Chertow, G. M., Coburn, J. W., Quarles, L. D., Goodman, W. G., Block, G. A., DrEke, T. B., Cunningham, J., Sherrard, D. J., Mccary, L. C., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67139.x · Cited by 327
Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation
Andress, D. L. (2006) · Kidney International · doi:10.1038/sj.ki.5000045 · Cited by 309
Renoprotective role of the vitamin D receptor in diabetic nephropathy
Zhang, Z., Sun, L., Wang, Y., Ning, G., Minto, A. W., Kong, J., Quigg, R. J., & Li, Y. C. (2008) · Kidney International · doi:10.1038/sj.ki.5002572 · Cited by 305
Metabolic Bone Disease in Chronic Kidney Disease
Martin, K. J., & González, E. A. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070771 · Cited by 288
Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm
Moe, S. M., Drüeke, T., Lameire, N., & Eknoyan, G. (2007) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2006.10.005 · Cited by 287
de Borst, M. H., Vervloet, M. G., ter Wee, P. M., & Navis, G. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121251 · Cited by 282
“(3) The subsequent higher levels of angiotensin II cause renal klotho loss and (4) disrupted FGF-23 signaling, impairing phosphaturia and rising FGF-23 levels.”
BackgroundParicalcitol Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy
Tan, X., Li, Y., & Liu, Y. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050520 · Cited by 280
Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease
Kovesdy, C. P. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.110 · Cited by 277
Stubbs, J. R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121385 · Cited by 276
Optimal Vitamin D Status: A Critical Analysis on the Basis of Evidence-Based Medicine
Bouillon, R., Van Schoor, N. M., Gielen, E., Boonen, S., Mathieu, C., Vanderschueren, D., & Lips, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1195 · Cited by 274
Levin, A., Djurdjev, O., Beaulieu, M., & Er, L. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.06.023 · Cited by 270
Lau, W. L., Leaf, E. M., Hu, M. C., Takeno, M. M., Kuro-o, M., Moe, O. W., & Giachelli, C. M. (2012) · Kidney International · doi:10.1038/ki.2012.322 · Cited by 267
Uhlig, K., Berns, J. S., Kestenbaum, B., Kumar, R., Leonard, M. B., Martin, K. J., Sprague, S. M., & Goldfarb, S. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.02.340 · Cited by 265
Blockade of Wnt/β-Catenin Signaling by Paricalcitol Ameliorates Proteinuria and Kidney Injury
He, W., Kang, Y. S., Dai, C., & Liu, Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121236 · Cited by 259
Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial
Wang, A. Y.-M., Fang, F., Chan, J., Wen, Y.-Y., Qing, S., Chan, I. H.-S., Lo, G., Lai, K.-N., Lo, W.-K., Lam, C. W.-K., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013010103 · Cited by 255
Vaidya, A., & Williams, J. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.09.007 · Cited by 151
Secondary Hyperparathyroidism: Pathophysiology and Treatment
Saliba, W., & El-Haddad, B. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.05.090026 · Cited by 133
Sambrook, P. N., Chen, J. S., March, L. M., Cameron, I. D., Cumming, R. G., Lord, S. R., Schwarz, J., & Seibel, M. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0307 · Cited by 132
Hyppönen, E., Berry, D., Cortina-Borja, M., & Power, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010801 · Cited by 96
Pollak, V. E., & Lorch, J. A. (2007) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-7-38 · Cited by 40
Metadata
- Authors
- Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-31
- Volume
- 349
- Issue
- 5
- Pages
- 446-456
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105417592
- Cited by
- 927
- References
- 25
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.